Niki Karachaliou MD, PhD

Dr. NIki Karachaliou, MD, Ph.D. is currently a Senior Medical Director at The Merck Group. She has a received Doctor of Medicine from The University of Crete. Dr. Niki Karachaliou is a Senior Medical Director within the division RD-DOO Clinical Oncology at Merck Healthcare KGaA. She completed her graduate studies at the University of Athens Medical School (1994-2002). She completed a three-year residency in internal medicine and a second three-year residency in medical oncology at the University Hospital of Heraklion, Crete, Greece (2005-2011). In 2012, she was accepted as a translational research fellow under the mentorship of world-renowned medical oncologist and translational researcher Dr. Rafael Rosell in Barcelona, Spain. From 2016 until 2018 she worked as a medical oncologist, and director of the Rosell Medical Oncology Service at University Hospital Sagrat Cor, QuironSalud, Barcelona, Spain. She was also leading the Translational Research Transcription Program at the Pangaea Oncology laboratory, Quiron-Dexeus University Hospital, Barcelona.

Dr. Karachaliou received her Ph.D. degree with distinctions in 2014 on “Prognostic and/or predictive value of ERCC1, BRCA1, ATP7B, PKM2, TOPOI, TOPOIIA, TOPOIIB, and CMYC genes in patients with small cell lung cancer (SCLC)” from University Hospital of Heraklion, Crete, Greece. She is one of the 100 global experts in the field of SCLC, who participated in an expert meeting for this disease hosted by the International Association for the Study of Lung Cancer (IASLC) on April 2015 at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Karachaliou has co-authored more than 200 papers published in prestigious international peer-reviewed journals. She has also served as Guest Editor for two special two-issue series in Translational Lung Cancer Research Journal, one special two-issue series in Cancer Biology and Medicine, and one special issue for Therapeutics Advances in Medical Oncology. Dr. Karachaliou is a regular conference speaker and has given presentations at some of the most important oncology congresses around the world including ASCO, IASLC, and ESMO.